Shenzhen Salubris Pharmaceuticals (002294.SZ): SAL0167 received clinical trial approval.
Xinlitai (002294.SZ) announced that the company has received the Clinical Trial Approval Notice approved and issued by the National Medical Products Administration, allowing the company to conduct clinical trials for the innovative drug SAL0167 tablets (project code: SAL0167) independently developed by the company for the treatment of hyperlipidemia.
Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that the company has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company to conduct clinical trials for the innovative drug SAL0167 tablets (project code: SAL0167) developed independently by the company for hyperlipidemia.
SAL0167 is a cyclic peptide drug with independent intellectual property rights owned by the company. The cyclic peptide has high affinity and specificity for the target, making SAL0167 a potential optimal solution for patients with high cholesterol who require potent lipid-lowering treatment. If successfully developed and approved for market, it is expected to provide new medication options for patients, improve patient compliance, meet unmet clinical needs, and further enrich the company's innovative product pipeline in the field of chronic diseases.
Related Articles
On July 8th, ZHOU HEI YA (01458) spent 106,700 Hong Kong dollars to repurchase 84,500 shares.
On July 8th, China Boto (03318) spent HK$2.2611 million to repurchase 836,000 shares.
XIAO NOODLES (02408) spent HKD 24,500 to repurchase 7,000 shares on July 8th.
On July 8th, ZHOU HEI YA (01458) spent 106,700 Hong Kong dollars to repurchase 84,500 shares.
On July 8th, China Boto (03318) spent HK$2.2611 million to repurchase 836,000 shares.
XIAO NOODLES (02408) spent HKD 24,500 to repurchase 7,000 shares on July 8th.
RECOMMEND
